B-Cell Depletion Strategy for AAV Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for eliminating anti-adeno-associated virus (AAV) neutralizing antibodies (NAbs) have limited success, preventing the re-administration of AAV gene therapy vectors due to cross-reactivity and precluding eligibility for patients with pre-existing NAbs.
Innovation Solution
Administering CD19 targeting agents, optionally combined with BCMA, BAFF, or TACI targeting agents, to deplete B cells and reduce neutralizing antibodies, followed by AAV vector administration to overcome NAb barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods (anti-CD20, plasmapheresis, rapamycin, IgG cleaving endopeptidase) are used to eliminate NAbs, then some reduction in neutralizing antibodies may be achieved, but the methods have limited success and cannot reliably enable re-administration
Solution Approach 1:
The patent extracts and selectively targets the B cell population (specifically CD19+ B cells) that produces neutralizing antibodies against AAV vectors. By removing this specific cell type through CD19-targeting agents, the method eliminates the source of NAbs more effectively than conventional approaches, enabling reliable re-administration of AAV vectors.
Solution Approach 2:
The patent performs preliminary B cell depletion before AAV vector re-administration. By pre-treating with CD19 targeting agents to reduce B cell numbers and NAb titers before the actual therapy administration, the method prepares the immune system to tolerate subsequent AAV exposure, overcoming the barrier to re-administration.
2Adaptability or versatility
If B cell depletion is performed to enable AAV re-administration, then neutralizing antibodies are reduced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent segments the B cell population into different subsets based on their expression of B cell activating factor (BAFF) and B cell maturation antigen (BCMA). By targeting specific subsets (particularly BAFF+ and BCMA+ cells), the method achieves more precise and effective NAb elimination while potentially reducing overall treatment complexity through focused targeting rather than broad depletion.
Solution Approach 2:
The patent utilizes changes in B cell phenotype and antigen expression as parameters to guide targeting. By monitoring and utilizing the expression levels of CD19, BAFF, and BCMA on B cells, the method dynamically adjusts targeting strategies to optimize NAb reduction while managing treatment complexity through data-driven approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces neutralizing antibodies to ≤1:5, allowing for successful re-administration of AAV vectors and transgene expression, as demonstrated by sustained depletion of B cells and plasma cells.
Implementation Method 1
The targeting agents induce antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC).
Implementation Method 2
The targeting agents induce antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC).
Data Source
AI summary
Compositions and methods for depleting B cells and/or eliminating neutralizing antibodies, particularly for AA V gene therapy administration, are disclosed. Neutralizing alloantibodies (NAbs) to adeno-associated virus (AAV) occur both naturally after exposure to the wildtype circulating virus and following AAV vector mediated gene therapies. When pre-existing, these NAbs preclude eligibility to receive curative AAV gene therapy vectors. Following AAV infusion, the development of NAbs preclude re-administration even with other vector serotypes due to cross-reactivity. Given waning of transgene activity seen in multiple AAV gene therapy trials for hemophilia and the potential need to boost responses with growth in pediatric patients, the ability to re-administer AAV vectors is critical.